| scholarly article | Q13442814 |
| P50 | author | Marcus Maurer | Q50039778 |
| P2093 | author name string | Sheldon Spector | |
| Allen Kaplan | |||
| Hsin-Ju Hsieh | |||
| Dennis A Wong | |||
| Edward Conner | |||
| Sarbjit Saini | |||
| Karin E Rosen | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | urticaria | Q187440 |
| placebo | Q269829 | ||
| histamine antagonist | Q324089 | ||
| P304 | page(s) | 567-73.e1 | |
| P577 | publication date | 2011-07-18 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria | |
| P478 | volume | 128 |
| Q42091038 | Anti-IgE Treatment for Disorders Other Than Asthma |
| Q38091754 | Anti-IgE--emerging opportunities for Omalizumab |
| Q93072365 | Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence |
| Q38022183 | Biologic agents in the treatment of urticaria |
| Q92247720 | Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis |
| Q28085614 | Biologics in asthma--the next step toward personalized treatment |
| Q37277398 | Biologics in dermatology |
| Q93385054 | Causal Relationship Between Anti-TPO IgE and Chronic Urticaria by In Vitro and In Vivo Tests |
| Q42736757 | Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations |
| Q90398003 | Chronic Spontaneous Urticaria: The Devil's Itch |
| Q88801238 | Chronic Urticaria: Comparisons of US, European, and Asian Guidelines |
| Q38445637 | Chronic spontaneous urticaria - a management pathway for patients with chronic spontaneous urticaria |
| Q56637625 | Chronic spontaneous urticaria - a management pathway for patients with chronic spontaneous urticaria |
| Q26777088 | Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy |
| Q26849258 | Chronic urticaria in adults: state-of-the-art in the new millennium |
| Q38266463 | Chronic urticaria: new management options |
| Q38773071 | Clinical dose-response for a broad set of biological products: A model-based meta-analysis |
| Q33588223 | Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin |
| Q91671713 | Clinical impact of omalizumab in refractory chronic urticaria: One centre experience |
| Q38861332 | Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria |
| Q52661824 | Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update. |
| Q38547047 | Current challenges and controversies in the management of chronic spontaneous urticaria |
| Q38985255 | Dermatologic uses of omalizumabtitle |
| Q36834774 | Diagnosis and treatment of urticaria and angioedema: a worldwide perspective |
| Q48256384 | Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients |
| Q42454334 | Drug therapies in dermatology. |
| Q47790656 | Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial |
| Q43470423 | Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature |
| Q37634331 | Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust |
| Q42025188 | Effects of omalizumab treatment in patients with refractory chronic urticaria |
| Q34727734 | Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study |
| Q38965393 | Efficacy of Treatment of Non-hereditary Angioedema |
| Q47960148 | Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice |
| Q26743369 | Guideline of Chronic Urticaria Beyond |
| Q50068947 | Human eosinophils and mast cells: Birds of a feather flock together |
| Q39003567 | Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients. |
| Q37554168 | IgE-Related Chronic Diseases and Anti-IgE-Based Treatments |
| Q33683786 | Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients |
| Q42976598 | Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases |
| Q52938044 | Management and treatment of chronic urticaria (CU). |
| Q45223665 | Management of chronic spontaneous urticaria in real life--in accordance with the guidelines? A cross-sectional physician-based survey study |
| Q92643892 | Management of chronic urticaria in children: a clinical guideline |
| Q92434582 | Management problems in severe chronic inducible urticaria: Two case reports |
| Q39012896 | Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria |
| Q38217720 | Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria |
| Q27001941 | New era of biologic therapeutics in atopic dermatitis |
| Q58707639 | Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab |
| Q36082959 | Omalizumab for Urticarial Vasculitis: Case Report and Review of the Literature |
| Q37431777 | Omalizumab for chronic urticaria in Latin America. |
| Q41991600 | Omalizumab for chronic urticaria: a case series and overview of the literature |
| Q52976551 | Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. |
| Q38754492 | Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature. |
| Q38310407 | Omalizumab for the treatment of chronic urticaria |
| Q38997626 | Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety |
| Q58727162 | Omalizumab for urticaria treatment in clinical practice: a case series |
| Q37634329 | Omalizumab in an allergology clinic: real life experience and future developments |
| Q50931521 | Omalizumab in chronic urticaria: a retrospective series of 15 cases. |
| Q38428381 | Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment |
| Q47731684 | Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data |
| Q93050496 | Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey |
| Q90269434 | Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis |
| Q34794295 | Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review |
| Q38248806 | Omalizumab: a review of its use in patients with chronic spontaneous urticaria |
| Q39122684 | Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses |
| Q39343082 | Patient-reported outcomes (PROs) in chronic urticaria |
| Q28073074 | Personalized Medicine in Allergy |
| Q38160274 | Pharmacotherapy of chronic spontaneous urticaria |
| Q34459030 | Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions |
| Q26767180 | Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients |
| Q99565406 | Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review |
| Q26783158 | Profile of omalizumab in the treatment of chronic spontaneous urticaria |
| Q47600430 | Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria |
| Q52693298 | Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States. |
| Q36517533 | Research needs in allergy: an EAACI position paper, in collaboration with EFA. |
| Q37121967 | Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria |
| Q41701492 | Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. |
| Q56444281 | Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria |
| Q38450662 | Role of biologics in intractable urticaria |
| Q41103914 | Serum Specific IgE to Thyroid Peroxidase Activates Basophils in Aspirin Intolerant Urticaria |
| Q35783662 | Structural and Physical Basis for Anti-IgE Therapy |
| Q35078702 | Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies |
| Q35478921 | Suppression of basophil FcɛRI activation by serum from active chronic idiopathic/spontaneous urticaria (CIU/CSU) subjects |
| Q34454209 | Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments |
| Q37217942 | TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients |
| Q38208428 | The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q41755302 | The potential role of omalizumab in the treatment of chronic urticaria |
| Q35923496 | The role of autoimmune testing in chronic idiopathic urticaria |
| Q38981770 | Therapy of antihistamine-resistant chronic spontaneous urticaria |
| Q39168827 | Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases. |
| Q41786093 | Treatment of chronic spontaneous urticaria |
| Q38148494 | Treatment of refractory chronic urticaria: current and future therapeutic options |
| Q34323869 | Treatment of severe cold contact urticaria with omalizumab: case reports |
| Q59135496 | Two decades with omalizumab: what we still have to learn |
| Q38188032 | Update and insights into treatment options for chronic spontaneous urticaria |
| Q38542586 | Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines |
| Q38118905 | Urticaria and autoimmunity: where are we now? |
| Q83144497 | [What's new in dermatological therapy?] |
Search more.